Approvals in 2016: the march of the checkpoint inhibitors
Ces articles analysent le rapport coût-efficacité des inhibiteurs de points de contrôle immunitaire, notamment les anticorps anti PD-1 et anti PD-L1, approuvés par la FDA en 2015 et 2016 dans le traitement des cancers
In 2016, FDA Oncology approved five new molecular entities and 17 efficacy supplements, including six accelerated approvals, 17 priority reviews, and 11 approvals of breakthrough-designated therapies. The FDA also approved five companion diagnostics, including a liquid biopsy test. One new anti-PD-L1 antibody was approved, along with six supplementary approvals of anti-PD-1/PD-L1 antibodies.